期刊： CANCER TREATMENT REVIEWS, 2023; 120 ()
Background: Primary cardiac angiosarcoma (PCA) is the most prevalent histological type of cardiac sarcoma but its rarity poses a challenge for standar......
期刊： CANCER TREATMENT REVIEWS, 2023; 115 ()
Background: The prognostic differences between HER2-zero and HER2-low breast cancer (BC) remain unclear. Purpose of this meta-analysis is to investiga......
期刊： CANCER TREATMENT REVIEWS, 2023; 115 ()
Metastatic colorectal cancer (mCRC) is a heterogenous disease caused by various genetic alterations. The BRAFV600E mutation occurs in approximately 8-......
期刊： CANCER TREATMENT REVIEWS, 2023; 119 ()
Background and scope: Poly(ADP-ribose) polymerase inhibitors (PARPi) have revolutionized cancer treatment in recent years. These drugs present a favor......
期刊： CANCER TREATMENT REVIEWS, 2023; 120 ()
Gastric cancer (GC) is a highly aggressive malignancy that remains a significant contributor to cancer-related mortality worldwide, despite a decline ......
期刊： CANCER TREATMENT REVIEWS, 2023; 116 ()
Lung cancer (LC) is the leading cause of cancer-related death worldwide, mostly because the lack of a screening program so far. Although smoking cessa......
期刊： CANCER TREATMENT REVIEWS, 2023; 118 ()
In unresectable stage III non-small cell lung cancer (NSCLC), the standard of care for most fit patients is con-current chemotherapy with normofractio......
期刊： CANCER TREATMENT REVIEWS, 2023; 120 ()
Background: It has been hypothesised that manipulation during surgery releases tumoral components into circulation. We investigate the effect of surge......
期刊： CANCER TREATMENT REVIEWS, 2023; 120 ()
Approximately 20% of breast cancers (BCs) overexpress human epidermal growth factor receptor 2 (HER2), a transmembrane glycoprotein with tyrosine kina......
期刊： CANCER TREATMENT REVIEWS, 2023; 121 ()
Breast cancer susceptibility gene 1 (BRCA1) and breast cancer susceptibility gene 2 (BRCA2) deleterious variants were the first and, still today, the ......
期刊： CANCER TREATMENT REVIEWS, 2023; 118 ()
Background: Antibody drug conjugates (ADCs) represent a revolutionary drug class in cancer therapy, combining the precision of targeted therapy with t......
期刊： CANCER TREATMENT REVIEWS, 2023; 121 ()
In the immunoncology era, growing evidence has shown a clear sex dimorphism in antitumor immune response with a potential impact on outcomes upon immu......
期刊： CANCER TREATMENT REVIEWS, 2023; 119 ()
Cancer has become a global health issue and liquid biopsy has emerged as a non-invasive tool for various applications. In cancer, circulating tumor DN......
期刊： CANCER TREATMENT REVIEWS, 2023; 120 ()
Progresses of systemic treatments in advanced non-small cell lung cancer (NSCLC), such as immune checkpoint blockers (ICB) and targeted therapies, led......
